Daewon Pharmaceutical Co Ltd

Daewon Pharmaceutical Co Ltd has a market price of 9,260 KRW and a market cap of 198.47 billion KRW, with a price-to-book ratio of 0.75 and a price-to-tangible-book ratio of 0.75. The company's liquidity position is characterized by a current ratio of 1.19 and a debt-to-equity ratio of 0.76, indicating a moderate level of leverage. However, the company's free cash flow is negative at -27.04 billion KRW, and capital expenditures are -42.13 billion KRW, suggesting significant outflows.

In terms of profitability, Daewon Pharmaceutical Co Ltd reported a net income of -1.38 billion KRW and an operating income of 1.78 billion KRW. The company's return on equity is -0.52%, and return on assets is -0.22%, both of which are below the industry median for pharmaceutical companies. These metrics indicate that the company is not generating sufficient returns to cover its cost of capital.

The company's revenue is concentrated in a single geographic region, South Korea, with no disclosed international operations. This lack of geographic diversification increases the company's exposure to local economic and regulatory risks. Additionally, the company does not report segment-specific revenue, making it difficult to assess the performance of different product lines or therapeutic areas.

Looking ahead, the company's revenue is expected to remain flat, with no significant growth anticipated in the next fiscal year. The company's recent financial performance, including a net loss and negative free cash flow, suggests that it may face challenges in maintaining or increasing its market share in the competitive pharmaceutical industry.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet short-term obligations. The company's liquidity position is further constrained by a negative free cash flow and significant capital expenditures, which may require additional financing.

Recent events, including analyst estimates and recommendations, suggest a mixed outlook for the company. The mean price target is 15,250 KRW, with a median price target of 16,000 KRW. The mean recommendation is 1.60, indicating a generally positive sentiment among analysts, with two strong-buy ratings and three buy ratings. However, the absence of hold or sell ratings suggests that analysts are not overly cautious about the company's prospects.

Daewon Pharmaceutical Co Ltd (003220.KS) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry-specific benchmarks and facilitating more precise sector-based analysis for investors and analysts. In terms of risk assessment, the company now carries a "low" dilution risk rating. This classification suggests that the likelihood of significant share count expansion or equity dilution is currently minimal, which is a positive indicator for existing shareholders concerned about the erosion of their ownership stakes. Conversely, the liquidity risk assessment has been established at a "medium" level. This designation indicates that while the stock is not facing immediate liquidity crises, there may be moderate constraints on trading volume or ease of execution, a factor that traders and institutional investors should monitor when planning entry or exit strategies. The company currently has coverage from two analysts, though it holds no index memberships and has no reported top holders or officers in the available data. These structural details, combined with the new risk and sector classifications, offer a foundational update to Daewon Pharmaceutical’s investment profile, highlighting a stable equity structure within a defined healthcare context but with moderate liquidity considerations.